Literature DB >> 24756629

Drug therapy for multiple sclerosis.

Eleonora Tavazzi1, Marco Rovaris1, Loredana La Mantia2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24756629      PMCID： PMC4119143          DOI： 10.1503/cmaj.130727

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  60 in total

1.  Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.

Authors:  Jerry S Wolinsky; Ponnada A Narayana; Paul O'Connor; Patricia K Coyle; Corey Ford; Kenneth Johnson; Aaron Miller; Lillian Pardo; Shaul Kadosh; David Ladkani
Journal:  Ann Neurol       Date:  2007-01       Impact factor: 10.422

2.  Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

Authors:  Daniel D Mikol; Frederik Barkhof; Peter Chang; Patricia K Coyle; Douglas R Jeffery; Steven R Schwid; Bettina Stubinski; Bernard M J Uitdehaag
Journal:  Lancet Neurol       Date:  2008-09-11       Impact factor: 44.182

3.  Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

Authors:  M Trojano; F Pellegrini; D Paolicelli; A Fuiani; G B Zimatore; C Tortorella; I L Simone; F Patti; A Ghezzi; V Zipoli; P Rossi; C Pozzilli; G Salemi; A Lugaresi; R Bergamaschi; E Millefiorini; M Clerico; G Lus; M Vianello; C Avolio; P Cavalla; V Lepore; P Livrea; G Comi; M P Amato
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

4.  Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Authors:  Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

5.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

Authors:  G Comi; V Martinelli; M Rodegher; L Moiola; O Bajenaru; A Carra; I Elovaara; F Fazekas; H P Hartung; J Hillert; J King; S Komoly; C Lubetzki; X Montalban; K M Myhr; M Ravnborg; P Rieckmann; D Wynn; C Young; M Filippi
Journal:  Lancet       Date:  2009-10-06       Impact factor: 79.321

Review 6.  Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis.

Authors:  R Zivadinov; A T Reder; M Filippi; A Minagar; O Stüve; H Lassmann; M K Racke; M G Dwyer; E M Frohman; O Khan
Journal:  Neurology       Date:  2008-07-08       Impact factor: 9.910

7.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

8.  250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

Authors:  Paul O'Connor; Massimo Filippi; Barry Arnason; Giancarlo Comi; Stuart Cook; Douglas Goodin; Hans-Peter Hartung; Douglas Jeffery; Ludwig Kappos; Francis Boateng; Vitali Filippov; Maria Groth; Volker Knappertz; Christian Kraus; Rupert Sandbrink; Christoph Pohl; Timon Bogumil; P O'Connor; M Filippi; B Arnason; S Cook; D Goodin; H-P Hartung; H-P Harung; L Kappos; D Jeffery; G Comi
Journal:  Lancet Neurol       Date:  2009-09-02       Impact factor: 44.182

Review 9.  Corticosteroids for the long-term treatment in multiple sclerosis.

Authors:  A Ciccone; S Beretta; F Brusaferri; I Galea; A Protti; C Spreafico
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245
View more
  6 in total

1.  Assessment of ability of human adipose derived stem cells for long term overexpression of IL-11 and IL-13 as therapeutic cytokines.

Authors:  Asma Eslami; Moein Dehbashi; Mehnoosh Ashja-Arvan; Hossein Salehi; Maryam Azimzadeh; Mazdak Ganjalikhani-Hakemi
Journal:  Cytotechnology       Date:  2020-09-15       Impact factor: 2.058

2.  Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating inflammation.

Authors:  Eiji Saito; Robert Kuo; Ryan M Pearson; Nishant Gohel; Brandon Cheung; Nicholas J C King; Stephen D Miller; Lonnie D Shea
Journal:  J Control Release       Date:  2019-02-27       Impact factor: 9.776

Review 3.  Neural Stem Cell-Based Regenerative Approaches for the Treatment of Multiple Sclerosis.

Authors:  Juan Xiao; Rongbing Yang; Sangita Biswas; Yunhua Zhu; Xin Qin; Min Zhang; Lihong Zhai; Yi Luo; Xiaoming He; Chun Mao; Wenbin Deng
Journal:  Mol Neurobiol       Date:  2017-05-02       Impact factor: 5.590

4.  Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.

Authors:  L Lavorgna; S Esposito; R Lanzillo; M Sparaco; D Ippolito; E Cocco; G Fenu; G Borriello; S De Mercanti; J Frau; R Capuano; F Trojsi; L Rosa; M Clerico; A Laroni; V Brescia Morra; G Tedeschi; S Bonavita
Journal:  J Neurol       Date:  2019-01-16       Impact factor: 4.849

Review 5.  Thyroid Hormone Potentially Benefits Multiple Sclerosis via Facilitating Remyelination.

Authors:  Mao Zhang; Ziyi Ma; Haochen Qin; Zhongxiang Yao
Journal:  Mol Neurobiol       Date:  2015-08-05       Impact factor: 5.590

6.  dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis.

Authors:  Sangho Lim; Won-Ju Kim; Yeon-Ho Kim; Sohee Lee; Ja-Hyun Koo; Jung-Ah Lee; Heeseok Yoon; Do-Hyun Kim; Hong-Jai Park; Hye-Mi Kim; Hong-Gyun Lee; Ji Yun Kim; Jae-Ung Lee; Jae Hun Shin; Lark Kyun Kim; Junsang Doh; Hongtae Kim; Sang-Kyou Lee; Alfred L M Bothwell; Minah Suh; Je-Min Choi
Journal:  Nat Commun       Date:  2015-09-15       Impact factor: 14.919
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.